Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance
{{output}}
Currently, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) represent the standard first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). However, as the disease progresses, targeted resistance inevitably deve... ...
